Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cantargia AB
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Cost of Revenue
-kr346.3m
CAGR 3-Years
-20%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Cost of Revenue
-kr61.6m
CAGR 3-Years
-41%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Cost of Revenue
-kr1.5B
CAGR 3-Years
-39%
CAGR 5-Years
-25%
CAGR 10-Years
-25%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Cost of Revenue
-kr5.4B
CAGR 3-Years
-18%
CAGR 5-Years
-13%
CAGR 10-Years
-18%
BioArctic AB
STO:BIOA B
Cost of Revenue
-kr50.9m
CAGR 3-Years
-30%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

Back to Top